ArticleSurgical endoscopy2026
Oncologic and survival outcomes of pT2N0 rectal adenocarcinoma treated by transanal local excision: a retrospective cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expanding the ESMO-MCBS: integrating organ preservation into clinical benefit assessment in rectal cancer.ESMO gastrointestinal oncology · 2026Article
- Peritoneal opening during transanal endoscopic microsurgery: can preoperative positioning assessment improve intraoperative management?Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal management of pT2N0 rectal adenocarcinoma remains controversial, especially when tumours are incidentally diagnosed after local excision. Although total mesorectal excision (TME) is the standard approach, its associated morbidity has led to the exploration of conservative strategies. This study compares oncologic outcomes amongst three post-excision management options: salvage surgery, adjuvant radiotherapy, and no further treatment.
methodsThis retrospective cohort comprised 90 patients with pT2N0 rectal adenocarcinoma who were treated by transanal excision at a single tertiary centre from 1993 to 2025. All patients were staged N0 on MRI and divided into three groups: Group A (no further treatment), Group B (adjuvant radiotherapy), and Group C (completion salvage surgery). The primary outcomes were overall survival (OS) and disease-free survival (DFS), with additional analyses of histopathologic prognostic factors.
resultsMedian follow-up was 31 months. OS varied significantly across groups (p = 0.015), with the highest survival in Group B, followed by Group C and Group A. DFS showed no significant difference between groups. Patients in Group B had the lowest mortality (8.7%) and recurrence (30.4%) rates. Tumour budding was a significant predictor of poor prognosis in multivariate analysis. Local excision alone was associated with higher recurrence and mortality rates.
conclusionIn selected patients with pT2N0 rectal cancer discovered after transanal excision, adjuvant radiotherapy may provide outcomes comparable to salvage surgery and serve as an alternative in patients not suitable for surgery. High-risk histopathologic features should inform further management, as local excision alone was associated with worse outcomes. Multidisciplinary evaluation remains crucial for treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.